Panelists discuss how the current treatment landscape for chronic graft-versus-host disease includes a range of immunosuppressive approaches, from traditional corticosteroids and calcineurin ...

Panelists discuss how physician assistants educate and empower chronic graft-versus-host disease patients and their caregivers to recognize, report, and manage symptoms effectively, detailing ...

“We [as oncology nurses] end up establishing good rapports with our patients, and we’re basically the frontlines to nutritional deficiencies,” DiRubbo said. “So assessing nutritional needs from the ...

Oncology nurses and APPs play a role in supporting caregivers while the patient they care for receives a diagnosis and cancer ...

Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.

Oncology nurses should inform patients about adverse events and the signs of interstitial lung disease before treating their breast cancer with T-DXd.

Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer ...

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...

Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine ...

The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...